BMY vs STRO · P/E 17, rev $48.19B vs rev $62.0M
Bristol-Myers Squibb Company (BMY) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the BMY and STRO stock pages for the full models.
Not investment advice.